freeze-thaw raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-26. Anything still debated is marked as such rather than presented as settled.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
== Synthesis == Synthesis of OPS is very similar to that of natural oligonucleotides. The difference is that the oxidation step is replaced by sulfur transfer reaction (sulfurization) and that the capping step is performed after the sulfurization. Of many reported reagents capable of the efficient sulfur transfer, only three are commercially available:
This orchid can, however, remain in bloom for up to two months. Each individual flower can remain fresh for as long as six weeks. In addition, this plant has been found to have potential medicinal benefits; for example one research article by Harikarnpakdee and Chowjarean found it specifically aided in wound healing in humans.
=== Engine === Chainsaw engines are traditionally either a two-stroke single-cylinder gasoline (petrol) internal combustion engine (usually with a cylinder volume of 30 to 120 cc) or an electric motor driven by a battery or electric power cord. In a petrol chainsaw, fuel is generally supplied to the engine by a carburetor at the intake. Two-stroke engines have been preferred for chainsaws due to their higher power-to-weight ratio and simplicity. Hydraulic power may be used for chainsaws for underwater use. To allow use in any orientation, modern gasoline chainsaws use a diaphragm carburetor, which draws fuel from the tank using the alternating pressure differential within the crankcase. Early engines used carburetors with gravity fed float chambers, which caused the engine to stall when tilted. The carburetor may need to be adjusted to maintain an appropriate idle speed and air-fuel ratio, such as when moving to a higher/lower altitude or as the air filter clogs. Carburetors are adjusted either by the operator or, in some saws, automatically by an electronic control unit. To prevent vibration induced injury and reduce user fatigue, saws generally have an anti-vibration system to physically decouple the handles from the engine and bar. This is achieved by constructing the saw in two pieces, connected by springs or rubber in the same way an automobile suspension isolates the chassis from the wheels and road. In cold weather, carburetor icing can occur, so many saws have a vent between the cylinders and carburetor which may be opened to allow hot air to pass.
When dried for eating, pine nuts are 2% water, 13% carbohydrates, 14% protein, and 68% fat (table). In a 100-gram (3+1⁄2-ounce) reference serving, dried pine nuts supply 2,815 kilojoules (673 kilocalories) of food energy and are a rich source (20% or more of the Daily Value, DV) of numerous dietary minerals, particularly manganese, copper, magnesium, and zinc, with substantial amounts of vitamin E, vitamin K, and the B vitamins, thiamin and niacin (table).
== History == The concept that insulin resistance may be the underlying cause of diabetes mellitus type 2 was first advanced by Professor Wilhelm Falta and published in Vienna in 1931, and confirmed as contributory by Sir Harold Percival Himsworth of the University College Hospital Medical Centre in London in 1936; however, type 2 diabetes does not occur unless there is concurrent failure of compensatory insulin secretion.
Sources: en.wikipedia.org
=== Etymology === The name estradiol derives from estra-, Gk. οἶστρος (oistros, literally meaning "verve or inspiration"), which refers to the estrane steroid ring system, and -diol, a chemical term and suffix indicating that the compound is a type of alcohol bearing two hydroxyl groups.
=== Pharmacokinetics === In the field of pharmacokinetics, steady state refers to the condition in which the rate of drug administration is balanced by the rate of drug elimination, resulting in a stable concentration of the drug in the bloodstream over time. This equilibrium typically occurs following repeated dosing or continuous infusion, and is used to ensure consistent therapeutic drug levels. For most drugs exhibiting first-order kinetics, steady state is generally achieved after approximately four to five half-lives, at which point the changes in plasma concentrations between doses become minimal and predictable. At steady state, drug concentrations do not remain at a single, unchanging value but rather fluctuate within a limited range bounded by peak (Cmax) and trough (Cmin) values across each dosing interval. Ideally, this range is maintained above the minimum effective (therapeutic) concentration and below the threshold for adverse effects, thereby achieving concentrations within the so-called therapeutic window.
== History == The physical principles of ion traps were first explored by F. M. Penning, who observed that electrons released by the cathode of an ionization vacuum gauge follow a long cycloidal path to the anode in the presence of a sufficiently strong magnetic field. Later Wolfgang Paul developed a method to trap ions without magnetic fields that was based on his work with quadrupole mass spectrometers. Ion traps were used in television receivers prior to the introduction of aluminized CRT faces around 1958, to protect the phosphor screen from ions. The ion trap must be delicately adjusted for maximum brightness.
=== Notable individuals === Charlie "Bird" Parker, the jazz saxophonist, is said to have used nutmeg recreationally. Malcolm X once tried nutmeg while in prison in 1946, remarking that it "had the kick of three or four reefers". Richard Meltzer, the rock critic, is known to have tried nutmeg, expressing that it caused him to experience all music as identical. William S. Burroughs tried nutmeg once and found it vaguely similar to cannabis but with more side effects.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.